These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12067933)

  • 1. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?
    Reid FD; Cook DG; Whincup PH
    Heart; 2002 Jul; 88(1):15-9. PubMed ID: 12067933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey.
    Haq IU; Ramsay LE; Wallis EJ; Isles CG; Ritchie LD; Jackson PR
    Heart; 2001 Sep; 86(3):289-95. PubMed ID: 11514481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used?
    Rowland Yeo K; Yeo WW
    Heart; 2002 May; 87(5):423-7. PubMed ID: 11997409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid levels and the use of lipid-lowering agents in England and Scotland.
    Primatesta P; Poulter NR
    Eur J Cardiovasc Prev Rehabil; 2004 Dec; 11(6):484-8. PubMed ID: 15580059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.
    Nag SS; Daniel GW; Bullano MF; Kamal-Bahl S; Sajjan SG; Hu H; Alexander C
    J Manag Care Pharm; 2007 Oct; 13(8):652-63. PubMed ID: 17970603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of statins after hospitalization for coronary heart disease.
    Ye X; Gross CR; Schommer J; Cline R; Xuan J; St Peter WL
    J Manag Care Pharm; 2007 Jun; 13(5):385-96. PubMed ID: 17605510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?
    Forge BH; Briganti EM
    Med J Aust; 2001 Nov; 175(9):471-5. PubMed ID: 11758075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
    Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
    Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study in primary care in patients without vascular disease comparing levels of coronary risk factors in those recommended for lipid-lowering drugs based on either absolute risk or absolute risk reduction.
    Ramachandran S; Croft P; Neary RH
    Prev Cardiol; 2003; 6(1):17-21. PubMed ID: 12624557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001.
    Tonstad S; Rosvold EO; Furu K; Skurtveit S
    J Intern Med; 2004 Apr; 255(4):494-502. PubMed ID: 15049884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework.
    Ramsay SE; Morris RW; Papacosta O; Lennon LT; Thomas MC; Whincup PH
    J Public Health (Oxf); 2005 Dec; 27(4):338-43. PubMed ID: 16162637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for inequalities in the management of coronary heart disease in Scotland.
    Simpson CR; Hannaford PC; Williams D
    Heart; 2005 May; 91(5):630-4. PubMed ID: 15831649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The causes and effects of socio-demographic exclusions from clinical trials.
    Bartlett C; Doyal L; Ebrahim S; Davey P; Bachmann M; Egger M; Dieppe P
    Health Technol Assess; 2005 Oct; 9(38):iii-iv, ix-x, 1-152. PubMed ID: 16181564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials.
    Pignone M; Phillips C; Mulrow C
    BMJ; 2000 Oct; 321(7267):983-6. PubMed ID: 11039962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low prevalence of lipid lowering drug use in older men with established coronary heart disease.
    Whincup PH; Emberson JR; Lennon L; Walker M; Papacosta O; Thomson A
    Heart; 2002 Jul; 88(1):25-9. PubMed ID: 12067936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering drug therapy in elderly patients.
    Berthold HK; Gouni-Berthold I
    Curr Pharm Des; 2011; 17(9):877-93. PubMed ID: 21418034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.
    Ansell BJ; Watson KE; Fogelman AM
    JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.